Corbus’ pipeline encompasses two different approaches to immunology: small molecules that activate or inhibit the body’s endocannabinoid system and monoclonal antibodies that target integrins to inhibit activation of TGFβ.
We are committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer.
We are a unique team of individuals who are high-achieving, innovative, creative, and above all else, passionate about what we do.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.
Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it will participate in the New York Academy of Sciences’ webinar on January 27, 2021 on the endocannabinoid system as a target for therapeutic agents.
Data about Corbus’ pipeline will be presented in the following sessions:
2. Talk: Therapeutic Potential of Targeting Cannabinoid Type 1 and Type 2 Receptors
For more information, visit http://www.corbuspharma.com/, and connect with us on Twitter, LinkedIn, and Facebook.
1. Talk: New Insights into the Resolution of Acute Inflammation in Humans Provided by — Lenabasum, a Synthetic Analogue of delta -8- tetrahydrocannabinol (THC)-11-oic Acid
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.